WO2018032785A1 - 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 - Google Patents
人成纤维细胞生长因子21融合蛋白及其制备方法与用途 Download PDFInfo
- Publication number
- WO2018032785A1 WO2018032785A1 PCT/CN2017/079871 CN2017079871W WO2018032785A1 WO 2018032785 A1 WO2018032785 A1 WO 2018032785A1 CN 2017079871 W CN2017079871 W CN 2017079871W WO 2018032785 A1 WO2018032785 A1 WO 2018032785A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion protein
- hfgf21
- amino acid
- protein according
- human
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 162
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 159
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 title claims description 143
- 102000056713 human FGF21 Human genes 0.000 title claims description 143
- 238000002360 preparation method Methods 0.000 title description 7
- 239000003814 drug Substances 0.000 claims abstract description 13
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 9
- 208000008589 Obesity Diseases 0.000 claims abstract description 9
- 235000020824 obesity Nutrition 0.000 claims abstract description 9
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 5
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 230000035772 mutation Effects 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 31
- 230000004927 fusion Effects 0.000 claims description 25
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 22
- 206010022489 Insulin Resistance Diseases 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 17
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 17
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 17
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 17
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 16
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 15
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 15
- 210000004899 c-terminal region Anatomy 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 102000005962 receptors Human genes 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 10
- 102220315697 rs1553622313 Human genes 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 7
- 230000013595 glycosylation Effects 0.000 claims description 7
- 238000006206 glycosylation reaction Methods 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 238000007792 addition Methods 0.000 claims description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 6
- MSBLMBWXUVQCDY-UHFFFAOYSA-N 1-(4,4-dimethyl-1-piperazin-4-iumyl)ethanone Chemical compound CC(=O)N1CC[N+](C)(C)CC1 MSBLMBWXUVQCDY-UHFFFAOYSA-N 0.000 claims description 5
- 101000988793 Homo sapiens Host cell factor C1 regulator 1 Proteins 0.000 claims description 5
- 101000613207 Homo sapiens Pre-B-cell leukemia transcription factor-interacting protein 1 Proteins 0.000 claims description 5
- 102100029105 Host cell factor C1 regulator 1 Human genes 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000003746 Insulin Receptor Human genes 0.000 claims description 4
- 108010001127 Insulin Receptor Proteins 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 102220516209 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial_Q55C_mutation Human genes 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102200072304 rs1057519530 Human genes 0.000 claims description 3
- 102200124454 rs80356507 Human genes 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims 5
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 235000009200 high fat diet Nutrition 0.000 description 55
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 46
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 28
- 239000008103 glucose Substances 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 235000015263 low fat diet Nutrition 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 239000007924 injection Substances 0.000 description 10
- 229940090044 injection Drugs 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 238000013116 obese mouse model Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000007446 glucose tolerance test Methods 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 102100020683 Beta-klotho Human genes 0.000 description 5
- 101710104526 Beta-klotho Proteins 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 101150074155 DHFR gene Proteins 0.000 description 4
- 108091008794 FGF receptors Proteins 0.000 description 4
- 101100350650 Fowlpox virus (strain NVSL) FPV167 gene Proteins 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 125000003147 glycosyl group Chemical group 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 201000005948 Donohue syndrome Diseases 0.000 description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 230000000636 anti-proteolytic effect Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 2
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000035369 Leprechaunism Diseases 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000013229 diet-induced obese mouse Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000003335 steric effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000010254 HAIR-AN syndrome Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000016140 Rabson-Mendenhall syndrome Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 101150005884 ctp1 gene Proteins 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013224 high-fat diet-induced obese mouse Methods 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- -1 linker amino acid Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000002732 pharmacokinetic assay Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a human fibroblast growth factor 21 (hFGF21) fusion protein, and to the use of the fusion protein for the preparation of a medicament for the treatment of diabetes, obesity, dyslipidemia and/or metabolic syndrome.
- hFGF21 human fibroblast growth factor 21
- Fibroblast growth factors (FGFs) family is a kind of polypeptide growth factor with various physiological functions.
- the mammalian FGF family has been found to have 22 members, which are divided into 7 subfamilies.
- Fibroblast growth factor 21 (FGF21) belongs to the FGF19/21/23 subfamily and is mainly expressed in the liver. It is also expressed in tissue cells related to glycolipid metabolism, such as adipose tissue, islet ⁇ cells, and muscle tissue. . Unlike other FGF members, this subfamily functions in an endocrine manner, involved in the regulation of energy and bile acid homeostasis, glucose and lipid metabolism, and homeostasis of phosphate and vitamin D (Moore DD et al., Science, 2007).
- the FGF21 mature protein consists of 181 amino acids. Unlike most members of the FGF family, FGF21 does not specifically bind to heparin to promote cell growth and differentiation.
- the C-terminus of FGF21 is closely related to its biological activity. The C-terminus of FGF21 directly binds to the cofactor ⁇ -Klotho, and then activates the FGFR receptor and downstream related signaling molecules, which in turn exerts its biological effects (Yie J et al., FEBS Lett, 2009, 583). (1): 19-24; and Micanovic R et al, J Cell Physiol, 2009, 219(2): 227-234).
- FGF21 regulates the expression of glucose transporter 1 (GLUT1) and promotes the uptake of glucose in 3T3-L1 cells and human primary adipocytes.
- GLUT1 glucose transporter 1
- FGF21 significantly reduces mouse body weight and blood glucose levels in genetically controlled or diet-induced obese mice, while also reducing triglyceride levels in the liver and serum, and also has an important effect on mouse insulin sensitivity ( Kharitonenkov A et al, Journal of clinical Investigation, 2005, 115(6): 1627-1635; Coskun T et al, Endocrinology, 2008, 149(12): 6018-6027; Xu J et al, Diabetes, 2009, 58(1): 250-259).
- Exogenous FGF21 in diet-induced obese mice and ob/ob mice can reverse liver hepatic degeneration and enhance hepatic insulin sensitivity (including reducing hepatic glucose production and increasing hepatic glycogen content), thereby improving systemic glucose intolerance Receptivity and insulin resistance (Xu J et al, Diabetes, 2009, 58(1): 250-259; Berglund ED et al, Endocrinology, 2009, 150(9): 4084-4093; Xu J et al, Am J Physiol Endocrinol Metab, 2009, 297(5)E1105-1104).
- FGF21 has the same metabolic regulation in diabetic monkeys, while also reducing LDL cholesterol and increasing HDL cholesterol concentration (Kharitonenkov A et al, Endocrinology, 2007, 148(2): 774-781).
- FGF21 has a very significant beneficial metabolic regulation effect on obese rodent and non-human primates.
- FGF21 which does not rely on insulin to regulate blood glucose levels, does not cause hypoglycemia when administered as a hypoglycemic agent in large doses.
- FGF21 is the only cytokine currently found in the FGF family that does not have mitogenic effects, thereby greatly reducing the risk of side effects in clinical use.
- FGF21 is a potential target for the treatment of obesity, type 2 diabetes and hyperlipidemia.
- natural FGF21 is difficult to be developed into clinical therapeutic biological agents. The main reasons include: 1. FGF21 protein has poor stability and is susceptible to protease hydrolysis or enzymatic degradation; 2. FGF21 conformation is very unstable It is prone to aggregation, low stability also increases the difficulty of FGF21 in large-scale production; 3.
- Natural FGF21 half-life is very short, human FGF21 has a half-life of 0.5-1 hour in mice, and half-life in cynomolgus monkeys 2-3 Hours (Kharitonenkov A et al, Journal of clinical Investigation, 2005, 115: 1627-1635). A variety of protein long-acting techniques have been reported to extend the in vivo half-life of recombinant FGF21.
- FGF21 is linked to a PEG molecule, increasing molecular weight, reducing glomerular filtration rate, and prolonging in vivo retention time (see patents WO2005/091944, WO2006/050247, WO2008/121563 and WO2012/066075); FGF21 and fatty acid long chain fusion ( Ability to bind serum albumin) (see WO2010/084169 and WO2012/010553); or to prepare an agonist antibody that specifically binds to the FGFR or FGFR/ ⁇ -klotho complex to mimic the mechanism of action of FGF21 to activate the FGF/FGFR signaling pathway ( See WO2011/071783, WO2011/130417, WO2012/158704 and WO2012/170438); or FGF21 half-life can be improved by fusion with Fc fragments (see WO2004/110472, WO2005/113606, WO2009/149171, WO2010/042747, WO2010/ 129503, WO2010/129600,
- Fc fusion technology In the field of protein drug long-acting technology, Fc fusion technology is the most widely used because it has fewer clinical side effects (for example, it is not easy to induce an allergic reaction or increase the toxicity of the drug due to prolonged half-life).
- the key to the development of FGF21/Fc long-acting fusion protein drugs lies in the following points: First, can we maintain FGF21 Biological activity.
- the C-terminus of FGF21 contains a binding site for ⁇ -Klotho, and thus fusion of Fc to the C-terminus of FGF21 results in a significant decrease in its activity, while fusion at the N-terminus retains its binding affinity to ⁇ -Klotho to the utmost extent.
- the Fc fragment is mostly fused to the N-terminus of FGF21 (Fc-FGF21); secondly, whether the fusion of Fc can significantly improve the pharmacokinetic properties of FGF21, and effectively extend its half-life to meet clinically twice a week or even once per week.
- the half-life improvement was not significant because the C-terminus of FGF21 in the fusion protein (especially between Pro171 and Ser172) was not protected by Fc and thus susceptible to Degradation occurs by protease attack (Hecht, R et al, PLoS One, 2012, 7: e49345).
- the ideal FGF21Fc fusion protein on the one hand, the anti-proteolytic ability of the C-terminus of FGF21 is enhanced, and a significantly extended half-life is obtained; on the other hand, the binding affinity of the C-terminus of FGF21 to ⁇ -Klotho is not due to the steric hindrance effect of Fc.
- the significant decrease leads to a significant decrease in its activity; at the same time, the introduction of fusion ligands and linker peptides does not increase its immunogenicity and can improve its stability.
- CTP human chorionic gonadotropin
- CTP acts as a linker between the beta subunit and the alpha subunit of follicle stimulating hormone; among the fusion proteins disclosed in WO2005058953A2, CTP is used as a linker for Linking the beta and alpha subunits of the glycoprotein hormone.
- the present inventors did not use CTP as a linker or as an extended half-life part according to the prior art, but instead linked it to a flexible peptide linker (for example, (GGGGS)n) to form a new linker sequence, which was placed between FGF21 and the extended half-life portion (
- a flexible peptide linker for example, (GGGGS)n
- an immunoglobulin Fc fragment but not including the CTP suggested by the prior art, constitutes a novel FGF21 fusion protein, thereby further extending the half-life and maintaining good biological activity and function.
- the object of the present invention is to solve the problems of short half-life, poor stability of FGF21, and to provide a highly glycosylated human FGF21 fusion protein with improved pharmaceutical properties, for example, enhanced proteolytic resistance, prolonged in vivo half-life and reduced aggregation.
- the present invention provides a hyperglycosylated human fibroblast growth factor 21 (hFGF21) fusion protein (hereinafter referred to as hFGF21 fusion protein), which comprises wild type human fibrils from N-terminal to C-terminal.
- hFGF21 hyperglycosylated human fibroblast growth factor 21
- hFGF21 fusion protein which comprises wild type human fibrils from N-terminal to C-terminal.
- Cell growth factor 21 or an analog thereof denoted as hFGF21
- L flexible peptide linker
- CTP carboxy terminal peptide rigid unit of at least one human chorionic gonadotropin beta subunit
- CTP human chorionic gonadotropin beta subunit
- fusion ligands eg, immunoglobulin and its Fc fragment, albumin or transferrin.
- the fusion proteins disclosed herein comprise a hFGF21 wild-type polypeptide, wherein the wild-type hFGF21 polypeptide comprises the sequence set forth in SEQ ID NO: 1 with amino acid leader 1-28 removed; or comprises 1- The amino acid leader peptide of 28 and having the equivalent sequence of SEQ ID NO: 1 substituted with G141S or L174P.
- the fusion proteins disclosed herein comprise an hFGF21 analog, eg, having one or more amino acid deletions, insertions, additions or substitutions relative to its wild-type sequence, and deletion of the N-terminus or C-terminus a truncated form of one or more amino acids; preferably, the hFGF21 analog is at least 70% homologous to the amino acid sequence of wild-type hFGF21; more preferably, the hFGF21 analog is at least 80% identical to the wild-type hFGF21 amino acid sequence More preferably, the hFGF21 analog is at least 90% homologous to the amino acid sequence of wild-type hFGF21. Most preferably, the hFGF21 analog is at least 95% homologous to the amino acid sequence of wild-type hFGF21.
- the flexible peptide linker is preferably non-immunogenic and produces sufficient distance between hFGF21 and the fusion ligand to minimize steric effects between each other.
- a flexible peptide linker comprising two or more amino acids is used and is selected from the group consisting of Gly (G), Ser (S), Ala (A) and Thr (T).
- the flexible peptide linker comprises G and S residues.
- the length of the linker peptide is very important for the activity of the fusion protein.
- the flexible peptide linker amino acid composition has the structural formula of (GS)a(GGS)b(GGGS)c(GGGGS)d, wherein a, b, c and d are greater than or equal to 0. An integer, and a+b+c+d ⁇ 1.
- the peptide linker is selected from the group consisting of:
- the CTP rigid unit is selected from the full length or truncated sequence consisting of amino acids 113 to 145 of the carboxy terminus of human chorionic gonadotropin ⁇ subunit, in particular, the CTP rigid unit comprises SEQ ID NO: 2 or its truncated sequence.
- the CTP rigid unit comprises at least 2 glycosylation sites; for example, in a preferred embodiment of the invention, the CTP rigid unit comprises 2 glycosylation sites, exemplarily, the CTP The rigid unit comprises 10 amino acids of the N-terminus of SEQ ID NO: 2, ie SSSS*KAPPPS*; or the CTP rigid unit comprises 14 amino acids of the C-terminus of SEQ ID NO: 2, ie S*RLPGPS*DTPILPQ; as another example Wherein the CTP rigid unit comprises 3 glycosylation sites, exemplarily, the CTP rigid unit comprises 16 amino acids of the N-terminus of SEQ ID NO: 2, ie SSSS*KAPPPS*LPSPS*R; In an embodiment, the CTP rigid unit comprises four glycosylation sites, exemplarily, the CTP rigid unit comprises 28, 29, 30, 31, 32 or 33 amino acids and begins with human chorionic gonadotropin The 113th, 114th, 115th, 116th, 117th or 118th position of
- the CTP rigid unit comprises 28 amino acids of the N-terminus of SEQ ID NO: 2, namely SSSS*KAPPPS*LPSPS*RLPGPS*DTPILPQ.
- * represents a glycosylation site.
- the CTP rigid units provided herein are at least 70% homologous to the native CTP amino acid sequence; in other embodiments, the CTP rigid units provided herein are at least 80% homologous to the native CTP amino acid sequence; In other embodiments, the CTP rigid units provided herein are at least 90% homologous to the native CTP amino acid sequence; in other embodiments, the CTP rigid units provided herein are at least 95% homologous to the native CTP amino acid sequence.
- the CTP rigid unit of the present invention may preferably comprise the following sequence:
- CTP1 SSSSKAPPPSLPSPSRLPGPSDTPILPQ;
- CTP2 PRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ;
- the fusion protein comprises one of the above CTP rigid units.
- the fusion protein of the present invention may further comprise one or more of the above CTP rigid units, preferably comprising 2, 3, 4 or 5 of the above CTP rigid units.
- the fusion protein comprises three CTP3 rigid units: SSSSKAPPPSSSSSKAPPPSSSSSKAPPPS (CTP3-CTP3-CTP3, or expressed as (CTP3) 3 ); in another embodiment of the invention, the fusion The protein comprises two CTP5 rigid units: SSSSKAPPPSLPSPSRSSSSKAPPPSLPSPSR (CTP5-CTP5, or expressed as (CTP5) 2 ).
- the fusion ligand is preferably an immunoglobulin Fc fragment; more preferably, the Fc fragment is preferably an Fc fragment from human immunoglobulin IgG, IgM, IgA and variants thereof; more preferably from human IgG1, IgG2, IgG3 or IgG4 and A variant Fc fragment, wherein the human IgG Fc variant (denoted as vFc) comprises at least one amino acid modification in wild-type human IgG Fc, and the Fc variant is non-lytic and exhibits minimal Fc - mediated adverse side effects (ADCC and CDC effects) and/or enhanced binding affinity to the FcRn receptor.
- ADCC and CDC effects minimal Fc - mediated adverse side effects
- human IgG Fc variant may be selected from the group consisting of:
- vFc ⁇ 1 human IgG1 hinge region, CH2 and CH3 regions containing the Leu234Val, Leu235Ala and Pro331Ser mutations (such as the amino acid sequence set forth in SEQ ID NO: 3);
- vFc ⁇ 2-1 human IgG2 hinge region, CH2 and CH3 region containing the Pro331Ser mutation (such as the amino acid sequence shown in SEQ ID NO: 4);
- vFc ⁇ 2-2 human IgG2 hinge region, CH2 and CH3 region containing the Thr250Gln and Met428Leu mutations (such as the amino acid sequence shown in SEQ ID NO: 5);
- vFc ⁇ 2-3 human IgG2 hinge region, CH2 and CH3 regions (such as the amino acid sequence shown in SEQ ID NO: 6) containing the Pro331Ser, Thr250Gln and Met428Leu mutations.
- vFc ⁇ 4 human IgG4 hinge region, CH2 and CH3 region containing the Ser228Pro and Leu235Ala mutations (such as the amino acid sequence shown in SEQ ID NO: 7).
- the IgG Fc variants provided by the present invention include, but are not limited to, the five variants described in (i) to (v), and may also be Combination or superposition of two types of functional variant mutation sites between IgG isotypes, as described in (iv) above, which is a new one obtained by superimposing the mutation sites in (ii) and (iii) A combined variant of IgG2Fc.
- An Fc variant (vFc) in a fusion protein of the invention which comprises a hinge region, a CH2 and a CH3 region of human IgG such as human IgG1, IgG2 and IgG4.
- This CH2 region contains amino acid mutations at positions 228, 234, 235 and 331 (as determined by the EU counting system). It is believed that these amino acid mutations reduce the effector function of Fc.
- Human IgG2 does not bind to FcyR but shows very weak complement activity.
- An Fc[gamma]2 variant with a Pro331Ser mutation should have a lower complement activity than native Fc[gamma]2 and is still an Fc[gamma]R non-binding element.
- IgG4Fc is defective in the activation of the complement cascade and its binding affinity to Fc ⁇ R is about an order of magnitude lower than that of IgG1.
- the Fc ⁇ 4 variant with the Ser228Pro and Leu235Ala mutations should exhibit minimal effector function compared to native Fc ⁇ 4.
- Fc ⁇ 1 with Leu234Val, Leu235Ala and Pro331Ser mutations also showed reduced effector function compared to native Fc ⁇ 1.
- These Fc variants are more suitable for the preparation of hFGF21 and its analog fusion proteins than native human IgG Fc.
- the 250 and 428 positions contain amino acid mutations that increase the binding affinity of the Fc region to the neonatal receptor FcRn, thereby further extending the half-life (Paul R et al, J Biol Chem, 2004, 279: 6213). – 6216); variants of the above two types of functions are combined or superimposed to obtain new combined variants, which reduce the effector function while prolonging its half-life.
- the Fc variants of the invention comprise, but are not limited to, mutations at several of the above sites, and substitutions at other sites may be introduced such that the Fc has reduced effector function and/or enhanced binding to the FcRn receptor, while still It does not cause a decrease in Fc variant function/activity or cause a poor conformational change.
- Common mutation sites can be found in Shields RL et al, J Biol Chem, 2001, 276(9):6591-604.
- amino acid sequence of the fusion protein is set forth in SEQ ID NO: 8.
- the fusion protein of the present invention is glycosylated; preferably, the fusion protein is glycosylated by expression in mammalian cells; more preferably, the fusion protein is passed through a Chinese hamster ovary cell Glycosylation is achieved by expression.
- a DNA encoding the above fusion protein is provided.
- the DNA sequence of the fusion protein is set forth in SEQ ID NO: 9.
- a carrier is provided.
- This vector contains the above DNA.
- a host cell comprises the vector described above or is transfected with the vector described above.
- the host cell is a CHO derived cell line DXB-11.
- a pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient or diluent, and an effective amount of the above fusion protein.
- fusion protein for the preparation of a medicament for treating a condition associated with FGF21, for example, obesity, type 1 or type 2 diabetes, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD) Non-alcoholic steatohepatitis (NASH), insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral arteries Disease, stroke, heart failure, coronary heart disease, kidney disease, diabetic complications, neuropathy, conditions associated with severe inactivation or mutation of the insulin receptor.
- a condition associated with FGF21 for example, obesity, type 1 or type 2 diabetes, pancreatitis, dyslipidemia, non-alcoholic fatty liver disease (NAFLD)
- NASH Non-alcoholic steatohepatitis
- insulin resistance hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, acute myocardial infarction, hypertension, cardiovascular disease, atherosclerosis, peripheral
- a mammalian cell line such as a CHO-derived cell line
- the mammalian cell in step (a) is a CHO cell; more preferably the CHO-derived cell line DXB-11.
- the hFGF21 fusion protein of the present invention has the following outstanding advantages:
- the hFGF21 fusion protein has an extended half-life of in vivo function.
- the hFGF21 fusion protein was administered for 16 hours.
- the medium and high dose groups significantly improved the glucose utilization level of obese mice.
- the high dose group could significantly improve the glucose of obese mice.
- the hFGF21 fusion protein has long-lasting effect on improving glucose utilization.
- this also demonstrates that the hFGF21 fusion protein has a significantly enhanced anti-proteolytic ability, which is not easily degraded in vivo and reduces or loses activity.
- the fusion protein constructed by the present invention is fused to the C-terminus of FGF21, and the protective effect of Fc reduces the susceptibility to proteolytic enzyme, so the N-terminal Fc fusion protein (Fc-FGF21) reported in the prior art is compared.
- the half-life has been greatly extended.
- the CTP rigid unit contains a glycosyl group, and the negatively charged, highly sialylated CTP rigid unit is able to counteract the clearance of the kidney and further prolong the half-life of the fusion protein.
- the CTP-containing hFGF21 fusion protein has a longer in vivo circulating half-life and higher bioavailability than the CTP-free hFGF21 fusion protein.
- the single-dose pharmacokinetic data showed that the circulating half-life T 1/2 of the 3F/kg hFGF21 fusion protein FP4I in SD rats was 29.81 ⁇ 1.56h, whereas the CTP-free hFGF21 fusion protein.
- the T 1/2 of FP4J is only 22.43 ⁇ 1.45h, which is greatly prolonged compared with the natural half-life of hFGF21 (the circulating half-life in rats is 1-1.5h), which greatly reduces the frequency of administration.
- the C-terminal fusion Fc (FGF21-Fc) of FGF21 often leads to a significant decrease in its activity
- the C-terminal Fc fusion protein constructed by the present invention utilizes a novel linker peptide, the linker peptide Consisting of a flexible peptide and a CTP rigid peptide
- the CTP rigid unit contains a plurality of O-glycosyl side chains, which can form a relatively stable stereo conformation, and can effectively isolate hFGF21 from Fc, thereby minimizing the Fc-induced
- the steric effect allows FGF21 to maintain better biological activity.
- the hFGF21 fusion protein can effectively control the body mass of obese mice induced by high fat diet, improve insulin resistance and hepatic steatosis, and exhibit significant inhibition of obesity.
- CTP is derived from natural human hCG, is non-immunogenic, and is more suitable as a linker peptide than a non-naturally encoded amino acid sequence.
- Fc variants with enhanced binding affinity to neonatal receptor (FcRn) can further extend the half-life of the fusion protein.
- the hFGF21 fusion protein constructed by the present invention exhibits stronger thermal stability during preparation and storage, and has a higher expression level. At the same time, in the highly concentrated preparation, the hFGF21 fusion protein is also less likely to aggregate.
- human FGF21 and hFGF21 refers to a wild type human FGF21 polypeptide and analogs thereof.
- the sequence of the wild-type hFGF21 protein is available from the UNIPERT database under accession number Q9NSA1.
- the precursor protein consists of 209 amino acids, including the signal peptide (amino acids 1-28) and the mature protein (amino acids 29-209).
- a wild-type hFGF21 isoform or allelic form having Pro instead of Leu (position 174 of SEQ ID NO: 1 of the present invention) in a mature protein is known, in particular, from US2001012628A1.
- Another wild type hFGF21 isoform Gly was substituted with Ser (in position 141 of SEQ ID NO: 1 of the present invention).
- Another isoform with a shorter signal peptide (in the present invention, Leu at position 23 of SEQ ID NO: 1) is known from WO 2003/011213 (see SEQ ID NO: 2 in the publication of WO 2003/011213, with 27 amino acid residues) Base signal peptide).
- the wild-type hFGF21 comprises the mature protein partial sequence (amino acids 29-209) shown by SEQ ID NO: 1 and L174P or G141S in place of the isoform-removed leader peptide; in addition, the above-mentioned 27 or 28 is added before these sequences are included.
- the full length sequence of the precursor protein of the amino acid signal peptide is included.
- the hFGF21 analog according to the invention refers to a polypeptide which is or can be deduced or derived from wild type human FGF21, in particular or can be derived from SEQ ID NO: 1, ie by its amino acid sequence modification. Such modifications, modifications, or alterations can include substitutions, deletions, and/or additions of one or more amino acids.
- the term "mutein” or “mutant” is sometimes used herein in place of the term “analog”.
- an amino acid may be added and/or deleted at the C-terminus, N-terminus or internal to the amino acid sequence (the amino acid added inside the sequence may be referred to as an insertion).
- Amino acids are preferably added and/or deleted at the C-terminus and/or the N-terminus, more preferably at the N-terminus.
- An amino acid sequence having a C-terminal or N-terminal deletion may also be referred to as a truncated sequence, which is capable of providing a similar activity to the un truncated form of the mature hFGF21 polypeptide, in some cases better activity This is known in the art and includes forms of N-terminal truncation or C-terminal truncation.
- the N-terminally truncated hFGF21 analog comprises 1, 2, 3, 4, 5, 6, 7 or 8 amino acid residues selected from the N-terminus of the deleted mature hFGF21 polypeptide.
- Peptide. N-terminally truncated hFGF21 polypeptide with less than 9 amino acid residues retains mature hFGF21 polypeptide Reduce the ability of an individual's blood sugar.
- the invention encompasses a truncated form of mature hFGF21 polypeptide or hFGF21 protein having an N-terminal truncation of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues. body.
- the C-terminally truncated hFGF21 analog comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 selected from the C-terminus of the mature hFGF21 polypeptide. Or a polypeptide of 12 amino acid residues.
- C-terminal truncated truncated FGF21 polypeptide with less than 13 amino acid residues in an in vitro ELK-luciferase assay (Yie J. et al., FEBS Letts, 2009, 583: 19-24)
- the efficacy is at least 50% of the efficacy of wild-type hFGF21, suggesting that these hFGF21 mutants retain the ability of mature hFGF21 polypeptide to lower blood glucose in an individual.
- the invention encompasses a truncated form having a C-terminal truncation of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues Mature hFGF21 polypeptide or hFGF21 protein variant.
- an hFGF21 analog is a truncated form of wild-type mature hFGF21 in which the four N-terminal amino acid residues (HPIP) of the mature protein are removed, as disclosed, for example, in WO2006/065582.
- This truncated form is believed to stimulate glucose uptake by mouse 3T3-L1 adipocytes at the same level as wild-type hFGF21.
- the truncated form of hFGF21 has the amino acid sequence shown in SEQ ID NO: 1 at 33-209, designated hFGF21 (HPIP - ).
- hFGF21 is a SEQ ID NO: 1 polypeptide (also referred to as "Met-hFGF21”) having an N-terminal Met.
- the N-terminal Met is added when hFGF21 is expressed in E. coli, see, for example, Table 6 in WO2006/050247.
- hFGF21 analog is the substitution/replacement of one or more amino acids in the hFGF21 wild-type precursor protein set forth in SEQ ID NO: 1, including but not limited to: Q55C, A109T, L126R, G148C , K150R, P158S, S195A, P199G, G202A.
- amino acid sequences containing other modified hFGF21 analogs are disclosed in, for example, WO2003/061712, WO2005/091944, WO2006/028595, WO2006/028714, WO2006/065582, and WO2008/121563.
- CTP is a short peptide derived from the carboxy terminus of the ⁇ -subunit of human chorionic gonadotropin (hCG).
- FSH follicle stimulating hormone
- LH luteinizing hormone
- TSH thyrotropin
- hCG chorionic gonadotropin
- the native CTP contains 37 amino acid residues with four O-glycosylation sites and a terminal sialic acid residue. Negatively charged, highly sialylated CTP is resistant to the clearance of the kidneys, thereby prolonging the half-life of the protein in the body.
- the inventors creatively linked at least one CTP polypeptide to a flexible linker of appropriate length, collectively as a linker peptide, for ligation of hFGF21 with a fusion ligand (eg, an immunoglobulin Fc fragment).
- hFGF21 N-terminal and C-terminal sequences of hFGF21 are critical for their function, and the spatial conformation of hFGF21 is complex and fragile, making it poorly stable, easily degradable and easily polymerized, and then linked to the fusion ligand, and its steric hindrance. The effect can interfere with its correct folding, causing its activity to drop significantly or even be lost, or to produce aggregates more easily.
- a CTP rigid unit between hFGF21 and the Fc variant an equivalent of a rigid linker peptide is added.
- the N-terminally fused hFGF21 does not affect the binding site of the Fc variant and FcRn, thereby affecting the half-life; in addition, the Protein A binding site of Fc is important for the purification step in the preparation process, and the CTP rigid unit is connected to ensure The N-terminally fused hFGF21 also does not "cover" its binding site to protein A.
- the addition of a CTP rigid unit also allows the Fc fragment of about 25 kD size to not interfere with the correct folding of the N-terminally fused hFGF21, resulting in a decrease or loss of its biological activity/function.
- CTP glycosyl side chain can reduce the sensitivity of the linker peptide to proteases, making the fusion protein less susceptible to degradation in the junction region.
- CTP is derived from native human hCG and is not immunogenic, and thus is more suitable for use as a linker peptide than a non-naturally encoded amino acid sequence.
- the Fc element is derived from the constant region Fc fragment of immunoglobulin IgG, which plays an important role in eradicating the immune defense of pathogens.
- the effector function of Fc-mediated IgG is exerted through two mechanisms: (1) binding to cell surface Fc receptors (Fc ⁇ Rs), digestion of pathogens by phagocytosis or cleavage or killer cells via antibody-dependent cellular cytotoxicity (ADCC) pathway , or (2) binding to C1q of the first complement component C1, eliciting a complement-dependent cytotoxicity (CDC) pathway, thereby lysing the pathogen.
- Fc ⁇ Rs cell surface Fc receptors
- ADCC antibody-dependent cellular cytotoxicity
- CDC complement-dependent cytotoxicity
- IgG1 and IgG3 efficiently bind to Fc ⁇ Rs, and the binding affinity of IgG4 to Fc ⁇ Rs is low, and the binding of IgG2 to Fc ⁇ Rs is too low to be determined, so human IgG2 has almost no ADCC effect.
- human IgG1 and IgG3 can also efficiently bind to C1q to activate the complement cascade.
- Human IgG2 binds relatively weakly to C1q, whereas IgG4 does not bind to C1q (Jefferis R et al, Immunol Rev, 1998, 163: 59-76), so the human IgG2 CDC effect is also weak.
- the most effective method is to mutate the complement and receptor binding domain of the Fc fragment, modulate the binding affinity of Fc to related receptors, reduce or eliminate ADCC and CDC effects, and retain only Fc. Long cycle half-life characteristics without cytotoxicity.
- the mutation sites can be found in Shields RL et al, J Biol Chem, 2001, 276(9): 6591-604 or Chinese invention patent CN 201280031137.2.
- Fc variant with enhanced binding affinity to neonatal receptor (FcRn)
- the plasma half-life of IgG depends on its binding to FcRn, which generally binds at pH 6.0 and dissociates at pH 7.4 (plasma pH). By studying the binding sites of the two, the site of binding to FcRn on IgG was engineered to increase the binding ability at pH 6.0. Mutations in some residues of the human Fc ⁇ domain important for binding to FcRn have been shown to increase serum half-life. Mutations in T250, M252, S254, T256, V308, E380, M428 and N434 have been reported to increase or decrease FcRn binding affinity (Roopenian et al, Nat. Rview Immunology 7: 715-725, 2007). Korean Patent No.
- KR10-1027427 discloses variants of trastuzumab (Herceptin, Genentech) having increased FcRn binding affinity, and these variants are selected from the group consisting of 257C, 257M, 257L, 257N, 257Y, 279Q, 279Y.
- Korean Patent Publication No. KR2010-0099179 provides variants of bevacizumab (Avastin, Genentech) and these variants include Amino acid modifications of N434S, M252Y/M428L, M252Y/N434S, and M428L/N434S, showing increased in vivo half-life.
- a condition associated with a severe inactivating mutation of the insulin receptor describes a condition in a subject having a mutation in the insulin receptor (or a protein directly downstream thereof) that causes severe insulin resistance, but usually does not have type 2 Obesity common in diabetes.
- subjects with these conditions exhibit a syndrome of type 1 diabetes and type 2 diabetes. Therefore, the affected subjects are basically divided into several categories according to the severity, including: type A diabetes resistance, type C insulin resistance (AKA HAIR-AN syndrome), Rabson-Mendenhall syndrome, Donohue's syndrome or dwarf disease ( Leprechaunism). These conditions are associated with very high levels of endogenous insulin, leading to elevated blood glucose levels.
- the affected subjects also have a variety of clinical features associated with "insulin toxicity", including androgen excess, polycystic ovary syndrome (PCOS), hirsutism and acanthosis nigricans (skin fold overgrowth and pigmentation).
- PCOS polycystic ovary syndrome
- hirsutism hirsutism
- acanthosis nigricans skin fold overgrowth and pigmentation
- Diabetes complications are dysfunctions in other parts of the body caused by chronic hyperglycemia such as diabetic nephropathy, diabetic neuropathy, diabetic foot (foot ulcer and hypotonic), and ocular lesions (retinopathy). Diabetes also increases the risk of heart disease and bone and joint disorders. Other long-term complications of diabetes include skin problems, digestive problems, sexual dysfunction, and tooth and gum problems.
- metabolic syndrome is a pathological condition in which a variety of metabolic components are abnormally aggregated, including: (1) abdominal obesity or overweight; (2) atherosclerosis dyslipidemia, such as high triglyceride (TG) Hypertension and high-density lipoprotein cholesterol (HDL-C) are low; (3) hypertension; (4) insulin resistance and/or impaired glucose tolerance. Some criteria also include microalbuminuria, hyperuricemia, and pro-inflammatory state (C-reactive protein CRP) and thrombotic state (fibrinogen elevation and plasminogen inhibitor-1, PAI-1) Increase.
- C-reactive protein CRP pro-inflammatory state
- thrombotic state fibrinogen elevation and plasminogen inhibitor-1, PAI-1
- Dyslipidemia is a condition of lipoprotein metabolism, including lipoprotein overproduction or defects. Dyslipidemia can be manifested by an increase in blood total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride concentrations, and a decrease in high-density lipoprotein (HDL) cholesterol.
- LDL low-density lipoprotein
- HDL high-density lipoprotein
- Non-alcoholic fatty liver disease is a liver disease unrelated to alcohol consumption and is characterized by hepatic steatosis.
- Non-alcoholic steatohepatitis is a liver disease that is not associated with alcohol consumption and is characterized by hepatic steatosis accompanied by inflammation and fibrosis in the lobule.
- Figure 1 shows SpeI/EcoRI in a PCDNA3.1 expression vector according to an embodiment of the present invention.
- the nucleotide sequence of the fragmented hFGF21 fusion protein and the deduced amino acid sequence are indicated by the ⁇ 1 microglobulin leader peptide (1-19, Marked), hFGF21 (20-200, P substituted L), flexible peptide linker (201-227, Mark), CTP 1 (228-255, to Marked) and vFc (256-478) constitute.
- FIG. 2-a hFGF21 fusion protein FP4I reduction and non-reduction SDS-PAGE electrophoresis results, from left to right band in order: NR (non-reducing); M (protein Marker); R (reductive).
- Figure 2-b Results of FP-HPLC detection of hFGF21 fusion protein FP4I.
- FIG 7, hFGF21 FP4I fusion protein in liver function in mice fed the high fat diet conditions (means ⁇ SEM, n 8 ); statistically different tag Note: Compared with low-fat diet group, # P ⁇ 0.05, # # P ⁇ 0.01; compared with the high fat diet group, * P ⁇ 0.05, ** P ⁇ 0.01.
- FIG. 15 Effect of hFGF21 fusion protein FP4I on liver histopathology of high-fat diet-fed mice; Note: A: low-fat diet group; B: high-fat diet group; C: high-fat diet combined with hFGF21 fusion protein group.
- FIG. 16 Effect of hFGF21 fusion protein FP4I on the pathological morphology of adipose tissue in mice fed with high fat diet; Note: A: low fat diet group; B: high fat diet group; C: high fat diet combined with hFGF21 fusion protein group.
- the fusion proteins of the invention are typically prepared by biosynthetic methods. According to the nucleotide sequence of the present invention, one skilled in the art can conveniently prepare the nucleic acid of the present invention by various known methods. These methods are, for example but not limited to, PCR, DNA synthesis, etc. For specific methods, see J. Sambrook, Molecular Cloning Experiment Guide. As an embodiment of the present invention, the nucleic acid sequence of the present invention can be constructed by a method of segmentally synthesizing a nucleotide sequence and performing overlap extension PCR.
- the invention also provides an expression vector comprising a sequence encoding a fusion protein of the invention and an expression control sequence operably linked thereto.
- operably linked or “operably linked” is meant a condition in which portions of a linear DNA sequence are capable of modulating or controlling the activity of other portions of the same linear DNA sequence. For example, if a promoter controls the transcription of a sequence, then it is operably linked to the coding sequence.
- the expression vector may be a commercially available vector such as, but not limited to, pcDNA3, pIRES, pDR, pUC18 or the like which can be used for expression of a eukaryotic cell system.
- pcDNA3, pIRES, pDR, pUC18 or the like which can be used for expression of a eukaryotic cell system.
- One skilled in the art can select a suitable expression vector based on the host cell.
- the recombinant enzyme expression vector of the present invention is prepared by cleavage and splicing of the enzyme and inserting the coding sequence of the fusion protein of the present invention into a suitable restriction site.
- the invention also provides a host cell expressing a fusion protein of the invention comprising a coding sequence for a fusion protein of the invention.
- the host cell is preferably a eukaryotic cell such as, but not limited to, CHO, COS cells, 293 cells, RSF cells and the like.
- the cell is a CHO cell which can express the fusion protein of the present invention well, and a fusion protein having good binding activity and good stability can be obtained.
- the present invention also provides a method for producing a fusion protein of the present invention using recombinant DNA, the steps of which include:
- Introduction of the coding sequence into a host cell can employ a variety of known techniques in the art such as, but not limited to, calcium phosphate precipitation, protoplast fusion, lipofection, electroporation, microinjection, reverse transcription, phage Transduction method, alkali metal ion method.
- the fusion protein obtained as described above can be purified to a substantially uniform property, such as a single band on SDS-PAGE electrophoresis.
- a commercially available ultrafiltration membrane can be used to separate the protein, for example, from Millipore, Pellicon, etc., and the expression supernatant is first concentrated.
- the concentrate may be further purified by gel chromatography or by ion exchange chromatography. For example, anion exchange chromatography (DEAE, etc.) or cation exchange chromatography.
- the gel matrix may be a matrix commonly used for protein purification such as agarose, dextran, polyamide, and the like.
- the Q- or SP- group is a preferred ion exchange group.
- the purified product may be further purified by hydroxyapatite adsorption chromatography, metal chelate chromatography, hydrophobic interaction chromatography and reversed-phase high performance liquid chromatography (RP-HPLC). All of the above purification steps can utilize different combinations to ultimately achieve a substantially uniform protein purity.
- an affinity chromatography column containing a specific antibody, receptor or ligand of the fusion protein can be used for expression
- the fusion protein was purified.
- the fusion polypeptide bound to the affinity column can be eluted using conventional methods such as high salt buffer, pH change, and the like.
- the amino terminus or carboxy terminus of the fusion protein may also contain one or more polypeptide fragments as a protein tag.
- Any suitable label can be used in the present invention.
- the label may be FLAG, HA, HA1, c-Myc, 6-His or 8-His, and the like. These tags can be used to purify the fusion protein.
- Example 1 Construction of an expression plasmid encoding the hFGF21Fc fusion protein
- the gene sequence encoding the ⁇ 1 microglobulin leader peptide and mature hFGF21 or its analog, flexible peptide linker, CTP rigid unit and human IgG Fc variant are artificially optimized CHO cell-preferred codons, full-length sequence Obtained by chemical synthesis methods.
- the purified fusion protein gene of hFGF21 or its analog was digested with SpeI and EcoRI, and inserted into the corresponding restriction site of plasmid PXY1A1 modified by PCDNA3.1 to obtain a fusion gene expression plasmid.
- This plasmid contains a cytomegalovirus early promoter which is an enhancer required for mammalian cells to express foreign genes at high levels.
- the plasmid also contains a selectable marker to have kanamycin resistance in bacteria and G418 resistance in mammalian cells.
- the PXY1A1 expression vector contains the mouse dihydrofolate reductase (DHFR) gene, thereby co-amplifying the fusion gene and the DHFR gene in the presence of methotrexate (MTX). (See U.S. Patent 4,399,216).
- the present invention constructs a series of fusion proteins of hFGF21 comprising wild-type hFGF21 and its analogs, different lengths of flexible peptide linkers (Linker) and several different subtypes of IgG Fc variants (vFc).
- the components are composed, and the position and length of the CTP rigid unit are also different.
- the nucleotide sequence and translated amino acid sequence of FP4I are shown in FIG. 1 .
- wild-type hFGF21 has the amino acid sequence shown in SEQ ID NO: 1 (denoted as hFGF21) and its isoform L174P hFGF21 (SEQ ID NO: 1 at position 174, Leu is replaced by Pro), and hFGF21 analog is preferred. comprises a truncated wild-type polypeptide hFGF21 hFGF21 (HPIP -), i.e., wild-type N- terminus of the mature protein deleted hFGF21 HPIP (having SEQ ID NO: 1 amino acid sequence of position 33-209).
- the hFGF21 analog also preferably includes a variant in which an amino acid is substituted/substituted, such as variant Q55C, which is obtained by replacing Gln at position 55 of SEQ ID NO: 1 with Cys, and several other variants include A109T, L126R K150R, P199G and G202A are also substituted by the amino acid of the corresponding site of SEQ ID NO: 1.
- the recombinant expression vector plasmid is transfected into a mammalian host cell line to express the hFGF21 fusion protein.
- a preferred host cell line is a DHFR enzyme deficient CHO-cell (see U.S. Patent No. 4,818,679).
- the host cell is selected from the CHO-derived cell line DXB11.
- a preferred method of transfection is electroporation, and other methods, including calcium phosphate co-precipitation, lipofection, can also be used.
- the transfected fusion protein gene was co-amplified with the DHFR gene in growth medium containing increasing concentrations of MTX.
- Subclones with positive dilution DHFR expression were gradually pressurized, and transfectants capable of growing in up to 6 ⁇ M MTX medium were screened, the secretion rate was determined, and a cell line highly expressing the foreign protein was selected.
- a cell line having a secretion rate of more than about 30 (preferably about 50) ⁇ g/10 6 (i.e., millions) of cells per 24 hours is subjected to adaptive suspension culture using serum-free medium, and then purified by conditioned medium. protein.
- the conditioned medium containing the fusion protein was titrated to pH 7-8 with 1 N NaOH and then filtered through a 0.45 micron nitrocellulose filter. The filtrate was loaded onto a phosphate buffered saline (PBS) equilibrated Protein A column. After the fusion protein is bound to the Protein A column, the effluent components are discarded. The column was washed with PBS until the OD value at 280 nm was less than 0.01. The bound fusion protein was then eluted with 0.1 M citrate buffer pH 3.75. The eluate was neutralized with 0.4 volume of 1 M K 2 HPO 4 and the fractions containing the purified protein were combined and dialyzed against PBS.
- PBS phosphate buffered saline
- Example 4 Effect of single injection of hFGF21 fusion protein on glucose utilization rate in obese mice induced by high fat diet
- mice 32 male C57BL/6J mice of SPF grade and 7 weeks old (purchased from Shanghai Slack Laboratory Animal Co., Ltd.) were selected. Breeding environment: temperature 22-25 ° C, relative humidity 45-65%, lighting time 12h / d.
- Mice were randomly divided into 4 groups according to body weight: control group, hFGF21 fusion protein FP4I 2.5 mg/kg group (low dose group), 5 mg/kg group (middle dose group) and 10 mg/kg group (high dose group). The mice in the administration group were subcutaneously injected with the corresponding drug solution, and the control mice were subcutaneously injected with PBS buffer.
- mice in each group were fasted for 16 hours to carry out the glucose tolerance test.
- the fasting blood glucose level of the mice was measured, and 2 g/kg glucose solution was intraperitoneally injected.
- the blood glucose levels after 15 min, 30 min, 60 min, 90 min, and 120 min of glucose injection were measured, and the area under the curve (iAUC) was calculated by the trapezoidal method.
- the mice in each group continued the glucose tolerance test in the same manner as above. Data were expressed as mean ⁇ standard error (means ⁇ SEM) and data were analyzed using SPSS 18.0 statistical software. Normal distribution, one-way ANOVA was used for the mean difference between groups, LSD test was used for variance homogeneity, Dunnet T3 test for variance variance; non-parametric test for non-normal distribution, P ⁇ 0.05 for significant statistics difference.
- hFGF21 fusion protein FP4I significantly improved the glucose utilization level of obese mice at 16 h after administration (P ⁇ 0.05).
- high doses still significantly improved glucose utilization levels in obese mice 48 h after administration (P ⁇ 0.05).
- the experimental results demonstrate that the hFGF21 fusion protein provided by the present invention has long-lasting effect on improving glucose utilization.
- mice induced by high-fat diet were randomly divided into 10 groups (6 in each group): FP4A, FP4B, FP4C, FP4D, FP4E, FP4F, FP4G, FP4H, and FP4J, and the control group.
- the mice in the drug-administered group were injected subcutaneously.
- the corresponding solution was 10 mg/kg, and the control mice were injected subcutaneously with PBS buffer.
- Glucose tolerance experiments were performed at 16 h and 48 h after injection, respectively.
- hFGF21 fusion proteins FP4A, FP4B, FP4C, FP4D, FP4E, FP4F, FP4G, FP4H and FP4J significantly improved glucose utilization in obese mice at 16 h after administration (P ⁇ 0.05).
- Figure 4a hFGF21 fusion proteins FP4A, FP4B, FP4C, FP4D, FP4E, FP4F, FP4G and FP4H significantly improved glucose utilization in obese mice 48 h after administration (P ⁇ 0.05), while FP4J group and control group There is no significant difference in blood glucose (Fig. 4b).
- the hFGF21 fusion protein provided by the present invention has strong anti-proteolytic ability, is not easily degraded in the body, thereby maintaining a long physiological activity, and CTP-containing with respect to CTP-free FP4J.
- the hFGF21 fusion protein FP4I showed a longer functional half-life in vivo, suggesting that the addition of CTP can further extend the in vivo functional half-life of hFGF21.
- the mouse anti-hFGF21 antibody (R&D, product number MAB25373-100) was coated with HRP-labeled goat anti-human IgG-Fc mAb (Jackson, Inc., Cat. No. 109-035-098).
- the data is then input into the analysis software PKSOLVER to obtain the pharmacokinetic parameters T 1/2 and AUC (0-t) of the drug to be tested in the blood.
- Example 6 Experimental study of hFGF21 fusion protein in preventing obesity, nonalcoholic steatosis, insulin resistance and hypercholesterolemia in mice fed with high fat diet
- the high fat diet combined with the FP4I group was injected subcutaneously with FP4I every 4 days at a dose of 3.6 mg/kg, and the low fat diet group and the high fat diet group were subcutaneously injected with PBS buffer for 116 days.
- each group of mice was fasted for 16 hours, weighed and tested for fasting blood glucose, and the whole eye was taken by eyeball, centrifuged at 2000 ⁇ g for 15 min, and serum was separated. The liver tissue was separated, and after washing with physiological saline, the filter paper was blotted and weighed.
- liver tissue Take 2 parts of liver tissue in the same part, 1 part is fixed in 10% formalin solution for HE staining, and the other part of liquid nitrogen is frozen and stored at -80 °C for liver index analysis.
- One side of the epididymal adipose tissue was taken and fixed in a 10% formalin solution for HE staining.
- mice were weighed once every 4 days, and the muscle, fat and body fluid contents of the mice were analyzed by time-domain NMR on the 104th day after the start of the experiment.
- the Ouba XL-200 automatic biochemical analyzer measures the concentrations of ALT, AST, HDL-c, LDL-c, TG and TC in serum, and the specific operation is carried out according to the instrument manual.
- mice in each group were fasted for 6 h (10:00 am-4:00 pm), and the blood glucose levels of each group were measured and weighed.
- the insulin solution was administered by intraperitoneal injection at a lean mass of 0.75 IU/kg.
- the blood glucose levels of the mice at 15 min, 30 min, 60 min, 90 min and 120 min after injection were measured, and the insulin tolerance curve was drawn.
- the AUC area was calculated by the trapezoidal method.
- the fasting serum insulin content of mice was measured by ELISA, and the insulin resistance index was calculated.
- Insulin resistance index fasting blood glucose value (mmol / L) ⁇ fasting insulin content (mIU / L) / 22.5.
- liver triglyceride content 2.4, liver triglyceride content
- mice were accurately weighed 50 mg of liver tissue, and the TG content in liver tissue was measured by Folch method. Results are expressed as TG content per mg of liver tissue.
- liver and adipose tissue of the same part were preserved in 10% formalin solution, and histopathological observation was performed by HE staining.
- the body weight, body mass increase and body fat content of the high-fat diet group increased significantly, showing obvious obesity symptoms.
- the hFGF21 fusion protein can significantly reduce the body mass increase and body fat content under high-fat diet feeding conditions. The results are shown in Figures 5-6.
- mice fed high-fat diet showed significant symptoms of insulin resistance.
- Serum insulin test results further indicate that mice have hyperinsulinemia and insulin resistance.
- the hFGF21 fusion protein can significantly improve the insulin resistance of mice under high-fat diet feeding conditions and alleviate the increase of fasting blood glucose. The results are shown in Figure 10-13.
- the liver tissue of the high-fat diet group showed obvious fatty degeneration, and the lipid droplet vacuoles were clearly visible and fused into a sheet-like structure, and the liver cell morphology was severely damaged.
- the fat cell cross-sectional area is significantly increased.
- the hFGF21 fusion protein significantly attenuated liver tissue steatosis and reduced the fat cell cross-sectional area.
- hFGF21 fusion protein can effectively control the body mass of obese mice induced by high fat diet, improve insulin resistance, relieve liver steatosis and hypercholesterolemia.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
Description
Claims (25)
- 人成纤维细胞生长因子21融合蛋白,所述融合蛋白从N端至C端依次包含野生型hFGF21或其类似物、柔性肽接头、至少1个人绒毛膜***β亚基羧基末端肽刚性单元和融合配体;其中,融合配体选自免疫球蛋白及其Fc片段、人血清白蛋白和转铁蛋白,优选地,所述融合配体为免疫球蛋白Fc片段。
- 如权利要求1所述的融合蛋白,其特征在于,所述融合蛋白是糖基化的;优选地,所述融合蛋白是通过在哺乳动物细胞中表达而实现糖基化的;更优选地,所述融合蛋白是通过在中国仓鼠卵巢细胞中表达而实现糖基化的。
- 如权利要求1所述的融合蛋白,其特征在于,所述野生型hFGF21包含去除了1-28位氨基酸前导肽的SEQ ID NO:1所示序列;或包含去除了1-28位氨基酸前导肽且具有G141S或L174P取代的SEQ ID NO:1所示同等型序列。
- 如权利要求1所述的融合蛋白,其特征在于,所述hFGF21类似物相对于野生型hFGF21的氨基酸序列具有一个或多个氨基酸缺失、***、添加或取代,以及缺失N-末端或C-末端的一个或多个氨基酸;优选地,所述hFGF21类似物与野生型hFGF21的氨基酸序列至少70%同源;较优选地,所述hFGF21类似物与野生型hFGF21氨基酸序列至少80%同源;更优选地,所述hFGF21类似物与野生型hFGF21的氨基酸序列至少90%同源;最优选地,所述hFGF21类似物与野生型hFGF21的氨基酸序列至少95%同源。
- 如权利要求4所述的融合蛋白,其特征在于,所述hFGF21类似物缺失N-末端的1、2、3、4、5、6、7或8个氨基酸残基。
- 如权利要求5所述的融合蛋白,其特征在于,所述hFGF21类似物缺失N-末端4个氨基酸HPIP。
- 如权利要求4所述的融合蛋白,其特征在于,所述hFGF21类似物缺失C-末端1、2、3、4、5、6、7、8、9、10、11或12个氨基酸残基。
- 如权利要求4所述的融合蛋白,其特征在于,所述hFGF21类似物包含选自Q55C、A109T、L126R、G148C、K150R、P158S、S195A、P199G和G202A的一个或多个氨基酸的取代。
- 如权利要求1所述的融合蛋白,其特征在于,所述柔性肽接头含有2个或更多个选自G、S、A和T的氨基酸。
- 如权利要求9所述的融合蛋白,其特征在于,所述柔性肽接头氨基酸组成的 结构通式为(GS)a(GGS)b(GGGS)c(GGGGS)d,其中a,b,c和d是大于或等于0的整数,且a+b+c+d≥1。
- 如权利要求10所述的融合蛋白,其特征在于,所述柔性肽接头的氨基酸选自如下序列:(i)GGGGS;(ii)GSGGGSGGGGSGGGGS;(iii)GSGGGGSGGGGSGGGGSGGGGSGGGGS;(iv)GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS;(v)GGGSGGGSGGGSGGGSGGGS;(vi)GGSGGSGGSGGS。
- 如权利要求1所述的融合蛋白,其特征在于,所述人绒毛膜***β亚基的羧基末端肽刚性单元包含SEQ ID NO:2或其截短的序列;其中,所述截短的序列包含至少2个糖基化位点。
- 如权利要求12所述的融合蛋白,其特征在于,所述人绒毛膜***β亚基的羧基末端肽刚性单元包含以下氨基酸序列:(i)SSSSKAPPPSLPSPSRLPGPSDTPILPQ;(ii)PRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ;(iii)SSSSKAPPPS;(iv)SRLPGPSDTPILPQ;(v)SSSSKAPPPSLPSPSR。
- 如权利要求1所述的融合蛋白,其特征在于,所述人绒毛膜***β亚基的羧基末端肽刚性单元与权利要求13所述融合蛋白中的CTP氨基酸序列至少具有70%,80%,90%或95%的同一性。
- 如权利要求1所述的融合蛋白,其特征在于,所述融合蛋白包含1、2、3、4或5个人绒毛膜***β亚基的羧基末端肽刚性单元。
- 如权利要求1所述融合蛋白,其特征在于,所述人免疫球蛋白Fc片段为具有降低的ADCC效应和/或CDC效应和/或与FcRn受体的结合亲和力增强的变体。
- 如权利要求16所述融合蛋白,其特征在于,所述Fc片段选自人IgG Fc变 体;更优选地,所述人IgG Fc变体选自:(i)含有Leu234Val、Leu235Ala和Pro331Ser突变的人IgG1绞链区、CH2和CH3区域;(ii)含有Pro331Ser突变的人IgG2绞链区、CH2和CH3区域;(iii)含有Thr250Gln和Met428Leu突变的人IgG2绞链区、CH2和CH3区域;(iv)含有Pro331Ser、Thr250Gln和Met428Leu突变的人IgG2绞链区、CH2和CH3区域;(v)含有Ser228Pro和Leu235Ala突变的人IgG4绞链区、CH2和CH3区域。
- 如权利要1所述的融合蛋白,其特征在于,所述融合蛋白的氨基酸序列如SEQ ID NO:8。
- 编码如权利要求1-18中任一项所述融合蛋白的DNA分子。
- 如权利要求19所述的DNA分子,其特征在于,所述DNA分子包含如SEQ ID NO:9所示的序列。
- 一种载体,其特征在于,包含如权利要求19或20所述的DNA分子。
- 一种宿主细胞,其特征在于,包含如权利要求21所述的载体,或者转染了权利要求19或20所述DNA分子的载体。
- 一种药物组合物,其特征在于,包括药学上可接受的载体、赋形剂或稀释剂,以及有效剂量的如权利要求1-18中任一项所述的融合蛋白。
- 一种制备如权利要求1-18中任一项所述融合蛋白的方法,所述方法包括:(a)将权利要求19或20所述编码融合蛋白的DNA序列引入哺乳动物细胞;(b)筛选步骤(a)中在其生长培养基中每24小时期间内,表达超过50μg/106(百万)个细胞的高产细胞株;(c)培养步骤(b)筛选到的细胞株,表达融合蛋白;(d)收获步骤(c)中得到的发酵液,纯化融合蛋白;优选地,所述步骤(a)中的哺乳动物细胞为CHO细胞;更优选地,所述哺乳动物细胞为CHO衍生细胞系DXB-11。
- 如权利要求1-18中任一项所述的融合蛋白在制备用于治疗肥胖、1型或2型糖尿病、胰腺炎、血脂异常、非醇型脂肪肝病(NAFLD)、非醇型脂肪性肝炎 (NASH)、胰岛素耐受、高胰岛素血症、葡萄糖不耐受、高血糖、代谢综合征、急性心肌梗塞、高血压、心血管病、动脉粥样硬化、外周动脉病、中风、心脏衰竭、冠心病、肾病、糖尿病并发症、神经病、与胰岛素受体的严重失活或突变相关的病症药物中的用途。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17840761.5A EP3620474A4 (en) | 2016-08-19 | 2017-04-10 | HUMAN FIBROBLAST GROWTH FACTOR 21 (HFGF21) FUSION PROTEIN, METHOD OF MANUFACTURING IT AND USES THEREOF |
CN201780000366.0A CN107995914A (zh) | 2016-08-19 | 2017-04-10 | 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 |
MX2019012081A MX2019012081A (es) | 2016-08-19 | 2017-04-10 | Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso. |
CA3059662A CA3059662C (en) | 2016-08-19 | 2017-04-10 | Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof |
US16/604,088 US20210380654A1 (en) | 2016-08-19 | 2017-04-10 | Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610694914.1 | 2016-08-19 | ||
CN201610694914.1A CN106317226B (zh) | 2016-08-19 | 2016-08-19 | 用于构建融合蛋白的连接肽 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018032785A1 true WO2018032785A1 (zh) | 2018-02-22 |
Family
ID=57744675
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/079871 WO2018032785A1 (zh) | 2016-08-19 | 2017-04-10 | 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 |
PCT/CN2017/079872 WO2018032786A1 (zh) | 2016-08-19 | 2017-04-10 | 人凝血因子ix融合蛋白及其制备方法与用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/079872 WO2018032786A1 (zh) | 2016-08-19 | 2017-04-10 | 人凝血因子ix融合蛋白及其制备方法与用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20210380654A1 (zh) |
EP (1) | EP3620474A4 (zh) |
CN (7) | CN107759697B (zh) |
CA (2) | CA3059994C (zh) |
MX (1) | MX2019012081A (zh) |
RU (1) | RU2736339C9 (zh) |
WO (2) | WO2018032785A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11471513B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same |
US11472863B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106256835A (zh) * | 2016-08-19 | 2016-12-28 | 安源医药科技(上海)有限公司 | 高糖基化人生长激素融合蛋白及其制备方法与用途 |
US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
CN108623693B (zh) * | 2017-03-20 | 2022-03-25 | 徐寒梅 | 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用 |
CN107012186A (zh) * | 2017-03-29 | 2017-08-04 | 江南大学 | 生产低聚果糖的方法 |
CN107082815A (zh) * | 2017-06-28 | 2017-08-22 | 杭州皓阳生物技术有限公司 | 一种fsh‑hsa融合蛋白及其制备方法 |
CN107312797B (zh) * | 2017-07-28 | 2021-06-18 | 广州中科蓝华生物科技有限公司 | 一种蛋白调控***及其制备方法和应用 |
CN109553684A (zh) * | 2017-09-25 | 2019-04-02 | 中国科学院过程工程研究所 | 一种纳米载体蛋白及其制备方法和应用 |
CN110028587B (zh) * | 2018-01-11 | 2021-10-08 | 安源医药科技(上海)有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
CN108383912A (zh) * | 2018-02-06 | 2018-08-10 | 清华大学 | 人工融合蛋白及其用途 |
CN108404119B (zh) * | 2018-05-07 | 2020-09-25 | 江苏康缘瑞翱生物医药科技有限公司 | Fgf-21类似物的制备及在血栓治疗中的应用 |
WO2019222295A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
CA3100005A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
CN109251896A (zh) * | 2018-08-13 | 2019-01-22 | 中山大学 | 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用 |
CN110950964B (zh) * | 2018-09-26 | 2021-06-18 | 安源医药科技(上海)有限公司 | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 |
CN109439679A (zh) * | 2018-10-09 | 2019-03-08 | 上海市儿童医院 | 一种高活性重组人凝血因子ix融合蛋白及其制备方法 |
MX2021005155A (es) * | 2018-11-01 | 2021-09-30 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpo biespecífico y uso del mismo. |
CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
CN111378045B (zh) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物 |
JPWO2020158691A1 (ja) * | 2019-01-28 | 2021-12-02 | 東レ株式会社 | 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体 |
JP2022522787A (ja) * | 2019-03-05 | 2022-04-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | ポリペプチド分子及びその適用 |
CN111944035B (zh) * | 2019-05-14 | 2022-08-12 | 温州医科大学 | Fgf4及其应用 |
CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
CN112138149A (zh) * | 2019-06-28 | 2020-12-29 | 北京基科晟斯医药科技有限公司 | 重组凝血因子viii制剂 |
CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
CN112279920B (zh) * | 2019-07-25 | 2024-01-16 | 安源医药科技(上海)有限公司 | FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途 |
CN114364796B (zh) * | 2019-09-02 | 2023-07-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
CN110713545B (zh) * | 2019-09-11 | 2021-10-22 | 潍坊医学院 | 一种人源程序性细胞死亡因子受体蛋白-1及其生产方法和应用 |
CN110846297B (zh) * | 2019-11-26 | 2023-04-07 | 温氏食品集团股份有限公司 | 一种多功能融合酶和多功能融合酶真核表达载体及其构建方法 |
WO2021133822A1 (en) * | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
CN113121696A (zh) * | 2019-12-31 | 2021-07-16 | 周易 | Fab改造诱导形成的双特异性抗体及其制备方法和用途 |
CN113444710A (zh) * | 2020-03-25 | 2021-09-28 | 上海英脉德医疗科技有限公司 | ACE2-Fc融合蛋白及其用途 |
CN113461827A (zh) * | 2020-03-31 | 2021-10-01 | 安源医药科技(上海)有限公司 | 高效分离纯化重组人凝血因子VIII Fc融合蛋白的方法 |
CN111499764B (zh) * | 2020-04-02 | 2022-02-08 | 北京翼方生物科技有限责任公司 | 一种具有***活性的长效融合蛋白 |
CN111635461A (zh) * | 2020-05-07 | 2020-09-08 | 乾元康安(苏州)生物科技有限公司 | 一种ACE2-Albumin重组蛋白及其制备方法和应用 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
AU2020204470B1 (en) * | 2020-07-03 | 2021-05-27 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
CN112375149B (zh) * | 2020-10-30 | 2023-04-18 | 沣潮医药科技(上海)有限公司 | Ace2免疫融合蛋白及其应用 |
CN114470000A (zh) * | 2020-11-11 | 2022-05-13 | 上海萨美细胞技术有限公司 | 无细胞脂肪提取液对非酒精性脂肪肝炎的治疗用途 |
CN112812192B (zh) * | 2021-01-22 | 2022-05-20 | 湖南大学 | 一种作为核酸-抗体共缀物通用载体的ProA/G-dRep融合蛋白及其应用 |
CN113265007B (zh) * | 2021-06-10 | 2022-02-15 | 江南大学 | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 |
WO2023280144A1 (zh) * | 2021-07-05 | 2023-01-12 | 上海翰森生物医药科技有限公司 | 一种融合蛋白及其医药用途 |
CN113527503A (zh) * | 2021-07-27 | 2021-10-22 | 福建医科大学 | 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白 |
CN113880954B (zh) * | 2021-09-29 | 2024-05-14 | 江苏大学 | 一种重组人生长激素及其构建方法和应用 |
WO2023122257A2 (en) * | 2021-12-22 | 2023-06-29 | La Jolla Institute For Immunology | Coronavirus spike glycoprotein with improved expression and stability |
CN114426569A (zh) * | 2022-01-25 | 2022-05-03 | 宁波甲贝医药科技有限公司 | 一种用于构建融合蛋白的连接肽 |
CN115141283A (zh) * | 2022-03-10 | 2022-10-04 | 厦门柏慈生物科技有限公司 | 一种融合蛋白、制备方法及其应用 |
CN114807265A (zh) * | 2022-03-31 | 2022-07-29 | 上海锐康生物技术研发有限公司 | 一种s-烟碱的合成方法 |
WO2023245543A1 (en) * | 2022-06-23 | 2023-12-28 | Ampsource Biopharma Shanghai Inc. | Uses of fgf21 fusion proteins |
CN117126832B (zh) * | 2023-10-26 | 2024-01-30 | 四川维亚本苑生物科技有限公司 | 一种重组人凝血因子ix融合蛋白及其制备方法 |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4818679A (en) | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
US20010012628A1 (en) | 1999-11-05 | 2001-08-09 | Pankaj Agarwal | sbgFGF-19a |
WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
WO2003061712A1 (en) | 2002-01-22 | 2003-07-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intracellular imaging and for differentiating between tumor- and non-tumor cells |
WO2004110472A2 (en) | 2003-06-12 | 2004-12-23 | Eli Lilly And Company | Fusion proteins |
WO2005058953A2 (en) | 2003-12-12 | 2005-06-30 | Regeneron Pharmaceuticals, Inc. | Ogh fusion polypeptides and therapeutic uses thereof |
WO2005091944A2 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
WO2005113606A2 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
WO2006028595A2 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006065582A2 (en) | 2004-12-14 | 2006-06-22 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2008121563A2 (en) | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
WO2009149171A2 (en) | 2008-06-04 | 2009-12-10 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010042747A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010084169A2 (en) | 2009-01-23 | 2010-07-29 | Novo Nordisk A/S | Fgf21 derivatives with albumin binder a-b-c-d-e- and their use |
KR20100099179A (ko) | 2007-12-26 | 2010-09-10 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
WO2010129503A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
WO2011071783A1 (en) | 2009-12-07 | 2011-06-16 | Amgen Inc. | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof |
WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
WO2012010553A1 (en) | 2010-07-20 | 2012-01-26 | Novo Nordisk A/S | N-terminal modified fgf21 compounds |
WO2012066075A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Methods of treating fgf21-associated disorders |
WO2012158704A1 (en) | 2011-05-16 | 2012-11-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
WO2012170438A2 (en) | 2011-06-06 | 2012-12-13 | Amgen Inc. | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR |
WO2013049247A1 (en) | 2011-09-26 | 2013-04-04 | Novartis Ag | Fusion proteins for treating metabolic disorders |
WO2013188181A1 (en) | 2012-06-11 | 2013-12-19 | Eli Lilly And Company | Fibroblast growth factor 21 proteins |
CN103539861A (zh) | 2013-11-01 | 2014-01-29 | 广州诺新生物技术有限公司 | 长效重组人促卵泡激素融合蛋白 |
CN103539869A (zh) | 2013-10-11 | 2014-01-29 | 浙江凯胜畜产品加工有限公司 | 一种提高粗肝素钠提取工艺酶解效率的方法 |
CN103539860A (zh) | 2013-11-01 | 2014-01-29 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
CN104114183A (zh) * | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
CN104693270A (zh) * | 2013-12-10 | 2015-06-10 | 清华大学 | 一种用于融合蛋白的连接肽 |
WO2016114633A1 (en) | 2015-01-16 | 2016-07-21 | Yuhan Corporation | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same |
CN106117370A (zh) * | 2016-08-19 | 2016-11-16 | 安源医药科技(上海)有限公司 | 高糖基化Exendin‑4及其类似物的融合蛋白、其制备方法和用途 |
CN106256835A (zh) * | 2016-08-19 | 2016-12-28 | 安源医药科技(上海)有限公司 | 高糖基化人生长激素融合蛋白及其制备方法与用途 |
CN106279437A (zh) * | 2016-08-19 | 2017-01-04 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN106279436A (zh) * | 2016-08-19 | 2017-01-04 | 安源医药科技(上海)有限公司 | 活化的人凝血因子vii融合蛋白及其制备方法与用途 |
CN106317226A (zh) * | 2016-08-19 | 2017-01-11 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
US6103501A (en) * | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
EP2077121B1 (en) | 2003-05-06 | 2011-02-09 | Syntonix Pharmaceuticals, Inc. | Clotting factor VII-Fc chimeric proteins for treatment of a hemostatic disorder |
CN101974090B (zh) | 2003-06-12 | 2015-06-17 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
CN1889937B (zh) | 2003-12-03 | 2011-02-09 | 诺和诺德公司 | 糖基聚乙二醇化的因子ⅸ肽 |
US20050250185A1 (en) | 2003-12-12 | 2005-11-10 | Murphy Andrew J | OGH fusion polypeptides and therapeutic uses thereof |
US20090043080A1 (en) | 2004-09-29 | 2009-02-12 | Novo Nordisk Healthcare A/G | Purification of a Bulk of a Factor VII Polypeptide by Fractionated Elution from an Anion-Exchange Material |
CN1331888C (zh) * | 2005-03-02 | 2007-08-15 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗人b细胞淋巴瘤的单链双特异性抗体 |
RU2415934C2 (ru) | 2005-04-13 | 2011-04-10 | Астразенека Аб | Клетка-хозяин, содержащая вектор для продуцирования белков, требующих гамма-карбоксилирования |
EP1746161A1 (en) * | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
EP1907540B1 (en) | 2005-07-22 | 2012-12-19 | Bayer HealthCare LLC | In-solution activation of factor vii |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
JP2012529463A (ja) | 2009-06-11 | 2012-11-22 | ノヴォ ノルディスク アー/エス | 2型糖尿病を治療するための、glp−1とfgf21との組合せ |
US9050318B2 (en) | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
CN102770450B (zh) | 2010-02-16 | 2015-12-02 | 诺沃—诺迪斯克有限公司 | 因子viii融合蛋白 |
SG186856A1 (en) | 2010-07-09 | 2013-02-28 | Biogen Idec Hemophilia Inc | Factor ix polypeptides and methods of use thereof |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
AU2011274423B2 (en) | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
PT2717898T (pt) | 2011-06-10 | 2019-05-20 | Bioverativ Therapeutics Inc | Compostos pró-coagulantes e processos para a sua utilização |
EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
WO2013009627A2 (en) | 2011-07-08 | 2013-01-17 | Biogen Idec Hemophilia Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
WO2013016454A1 (en) | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
PT2802668T (pt) | 2012-01-12 | 2018-12-04 | Puget Sound Blood Center | Processos para reduzir a imunogenicidade contra o fator viii em indivíduos a receber terapêutica com fator viii |
CA2870621C (en) | 2012-02-14 | 2022-08-09 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
WO2013152351A2 (en) | 2012-04-06 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Fusion polypeptides and methods of use thereof |
EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | CHIMERIC COAGULATION FACTORS |
JP2015521589A (ja) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | プロコアグラント化合物 |
EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
EP3674410A1 (en) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
WO2014018777A2 (en) | 2012-07-25 | 2014-01-30 | Biogen Idec Ma Inc. | Blood factor monitoring assay and uses thereof |
EP2882457A1 (en) | 2012-08-13 | 2015-06-17 | Novo Nordisk A/S | Liquid factor viii formulations |
JP2015533483A (ja) | 2012-09-07 | 2015-11-26 | サノフイ | メタボリックシンドロームを治療するための融合タンパク質 |
JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
WO2014052490A1 (en) * | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
EP2908847B1 (en) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
AU2013349239B2 (en) * | 2012-11-20 | 2018-04-12 | Opko Biologics Ltd. | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
EP2938637A2 (en) | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Multivalent binding protein compositions |
PL3666283T3 (pl) | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
TW201536811A (zh) | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合fvii-xten分子及其用途 |
CN103599527A (zh) * | 2013-08-16 | 2014-02-26 | 安源生物科技(上海)有限公司 | 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物 |
CN103397009B (zh) * | 2013-08-16 | 2015-06-03 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
CN103554268B (zh) * | 2013-11-01 | 2015-04-01 | 广州联康生物科技有限公司 | 长效重组促卵泡激素及其应用 |
CN103539862B (zh) | 2013-11-01 | 2015-04-01 | 广州联康生物科技有限公司 | 一种长效重组促卵泡激素及其应用 |
CN103539868B (zh) | 2013-11-01 | 2016-05-04 | 上海春露生物化学有限公司 | 一种制备羧甲基壳聚糖的方法 |
CN103897064B (zh) | 2013-11-29 | 2016-05-11 | 广州优联康医药科技有限公司 | 长效重组人绒促性素融合蛋白 |
JP2017502036A (ja) * | 2013-12-23 | 2017-01-19 | シーエスエル、リミテッド | 血友病の予防的処置のための第ix因子を含む融合タンパク質およびその方法 |
CN105753945B (zh) * | 2014-12-15 | 2019-04-09 | 清华大学无锡应用技术研究院 | 一种连接肽及其应用 |
CN104558191B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd20×cd3的构建及应用 |
JP7096668B2 (ja) * | 2015-06-19 | 2022-07-06 | オプコ バイオロジクス リミテッド | 長時間作用型凝固因子およびその製造方法 |
KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
US11123438B2 (en) * | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
CN110028587B (zh) | 2018-01-11 | 2021-10-08 | 安源医药科技(上海)有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
-
2016
- 2016-08-19 CN CN201710628688.1A patent/CN107759697B/zh active Active
- 2016-08-19 CN CN201710599601.2A patent/CN107759694B/zh active Active
- 2016-08-19 CN CN201610694914.1A patent/CN106317226B/zh active Active
- 2016-08-19 CN CN201710564425.9A patent/CN107759696A/zh active Pending
-
2017
- 2017-04-10 MX MX2019012081A patent/MX2019012081A/es unknown
- 2017-04-10 WO PCT/CN2017/079871 patent/WO2018032785A1/zh unknown
- 2017-04-10 US US16/604,088 patent/US20210380654A1/en active Pending
- 2017-04-10 CN CN201780000366.0A patent/CN107995914A/zh active Pending
- 2017-04-10 RU RU2019135518A patent/RU2736339C9/ru active
- 2017-04-10 CA CA3059994A patent/CA3059994C/en active Active
- 2017-04-10 US US16/604,081 patent/US11472863B2/en active Active
- 2017-04-10 CA CA3059662A patent/CA3059662C/en active Active
- 2017-04-10 WO PCT/CN2017/079872 patent/WO2018032786A1/zh active Application Filing
- 2017-04-10 EP EP17840761.5A patent/EP3620474A4/en active Pending
- 2017-04-10 CN CN201910687158.3A patent/CN110229238B/zh active Active
- 2017-04-10 CN CN201780000362.2A patent/CN108137708B/zh active Active
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4818679A (en) | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
US20010012628A1 (en) | 1999-11-05 | 2001-08-09 | Pankaj Agarwal | sbgFGF-19a |
WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
WO2003061712A1 (en) | 2002-01-22 | 2003-07-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Diagnostic conjugate useful for intracellular imaging and for differentiating between tumor- and non-tumor cells |
WO2004110472A2 (en) | 2003-06-12 | 2004-12-23 | Eli Lilly And Company | Fusion proteins |
WO2005058953A2 (en) | 2003-12-12 | 2005-06-30 | Regeneron Pharmaceuticals, Inc. | Ogh fusion polypeptides and therapeutic uses thereof |
WO2005091944A2 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
WO2005113606A2 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
WO2006028595A2 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
WO2006065582A2 (en) | 2004-12-14 | 2006-06-22 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2008121563A2 (en) | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
KR20100099179A (ko) | 2007-12-26 | 2010-09-10 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
WO2009149171A2 (en) | 2008-06-04 | 2009-12-10 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010042747A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010084169A2 (en) | 2009-01-23 | 2010-07-29 | Novo Nordisk A/S | Fgf21 derivatives with albumin binder a-b-c-d-e- and their use |
WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2010129503A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
WO2011071783A1 (en) | 2009-12-07 | 2011-06-16 | Amgen Inc. | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof |
WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
WO2012010553A1 (en) | 2010-07-20 | 2012-01-26 | Novo Nordisk A/S | N-terminal modified fgf21 compounds |
CN103328502A (zh) * | 2010-11-19 | 2013-09-25 | 诺瓦提斯公司 | 治疗fgf21相关的病症的方法 |
WO2012066075A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Methods of treating fgf21-associated disorders |
WO2012158704A1 (en) | 2011-05-16 | 2012-11-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
WO2012170438A2 (en) | 2011-06-06 | 2012-12-13 | Amgen Inc. | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR |
WO2013049247A1 (en) | 2011-09-26 | 2013-04-04 | Novartis Ag | Fusion proteins for treating metabolic disorders |
CN103945871A (zh) * | 2011-09-26 | 2014-07-23 | 诺华股份有限公司 | 用于治疗代谢疾病的融合蛋白 |
CN104114183A (zh) * | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
WO2013188181A1 (en) | 2012-06-11 | 2013-12-19 | Eli Lilly And Company | Fibroblast growth factor 21 proteins |
CN103539869A (zh) | 2013-10-11 | 2014-01-29 | 浙江凯胜畜产品加工有限公司 | 一种提高粗肝素钠提取工艺酶解效率的方法 |
CN103539861A (zh) | 2013-11-01 | 2014-01-29 | 广州诺新生物技术有限公司 | 长效重组人促卵泡激素融合蛋白 |
CN103539860A (zh) | 2013-11-01 | 2014-01-29 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
CN104693270A (zh) * | 2013-12-10 | 2015-06-10 | 清华大学 | 一种用于融合蛋白的连接肽 |
WO2016114633A1 (en) | 2015-01-16 | 2016-07-21 | Yuhan Corporation | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same |
CN106117370A (zh) * | 2016-08-19 | 2016-11-16 | 安源医药科技(上海)有限公司 | 高糖基化Exendin‑4及其类似物的融合蛋白、其制备方法和用途 |
CN106256835A (zh) * | 2016-08-19 | 2016-12-28 | 安源医药科技(上海)有限公司 | 高糖基化人生长激素融合蛋白及其制备方法与用途 |
CN106279437A (zh) * | 2016-08-19 | 2017-01-04 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
CN106279436A (zh) * | 2016-08-19 | 2017-01-04 | 安源医药科技(上海)有限公司 | 活化的人凝血因子vii融合蛋白及其制备方法与用途 |
CN106317226A (zh) * | 2016-08-19 | 2017-01-11 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
Non-Patent Citations (21)
Title |
---|
"UNIPROT", Database accession no. Q9NSA1 |
BEENKEN, NATURE REVIEWS DRUG DISCOVER, vol. 8, 2009, pages 235 |
BERGLUND ED, ENDOCRINOLOGY, vol. 150, no. 9, 2009, pages 4084 - 4093 |
COSKUN T, ENDOCRINOLOGY, vol. 149, no. 12, 2008, pages 6018 - 6027 |
DATTA-MANNAN A ET AL.: "MAbs", vol. 4, 2012, TAYLOR & FRANCIS, pages: 267 - 273 |
FARES FA ET AL., PROC NATL ACAD SCI USA, vol. 89, 1992, pages 4304 - 4308 |
JEFFERIS R ET AL., IMMUNOL REV, vol. 163, 1998, pages 59 - 76 |
KHARITONENKOV A, ENDOCRINOLOGY, vol. 148, no. 2, 2007, pages 774 - 781 |
KHARITONENKOV A, JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 6, 2005, pages 1627 - 1635 |
MICANOVIC R, J CELL PHYSIOL, vol. 219, no. 2, 2009, pages 227 - 234 |
MOORE DD, SCIENCE, vol. 316, 2007, pages 1436 - 1438 |
OLANDER RM, DEV BIOL STAND, vol. 86, 1996, pages 338 |
PAUL R ET AL., J BIOL CHEM, vol. 279, 2004, pages 6213 - 6216 |
PAUL R. HINTON ET AL., J IMMUNOL, vol. 176, 2006, pages 346 - 356 |
ROOPENIAN ET AL., NAT.REVIEW IMMUNOLOGY, vol. 7, 2007, pages 715 - 725 |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SHIELDS RL ET AL., J BIOL CHEM, vol. 276, no. 9, 2001, pages 6591 - 604 |
XU J, AM J PHYSIOL ENDOCRINOL METAB, vol. 297, no. 5, 2009, pages E1105 - 1104 |
XU J, DIABETES, vol. 58, no. 1, 2009, pages 250 - 259 |
YIE J, FEBS LETT, vol. 583, no. 1, 2009, pages 19 - 24 |
YIE J. ET AL., FEBS LETTS, vol. 583, 2009, pages 19 - 24 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11471513B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same |
US11472863B2 (en) | 2016-08-19 | 2022-10-18 | Ampsource Biopharma Shanghai Inc. | Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA3059994C (en) | 2023-11-07 |
CN108137708A (zh) | 2018-06-08 |
EP3620474A1 (en) | 2020-03-11 |
CN110229238A (zh) | 2019-09-13 |
CA3059662A1 (en) | 2018-02-22 |
WO2018032786A1 (zh) | 2018-02-22 |
US20210380654A1 (en) | 2021-12-09 |
CN107995914A (zh) | 2018-05-04 |
US20200157185A1 (en) | 2020-05-21 |
CA3059994A1 (en) | 2018-02-22 |
CN107759694A (zh) | 2018-03-06 |
US11472863B2 (en) | 2022-10-18 |
CN106317226A (zh) | 2017-01-11 |
CN110229238B (zh) | 2020-10-09 |
CN107759697A (zh) | 2018-03-06 |
CN106317226B (zh) | 2017-09-05 |
CN107759696A (zh) | 2018-03-06 |
EP3620474A4 (en) | 2021-03-03 |
CN107759697B (zh) | 2023-03-24 |
CA3059662C (en) | 2023-11-14 |
RU2736339C9 (ru) | 2021-05-28 |
RU2736339C1 (ru) | 2020-11-16 |
MX2019012081A (es) | 2020-11-13 |
CN107759694B (zh) | 2023-01-13 |
CN108137708B (zh) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018032785A1 (zh) | 人成纤维细胞生长因子21融合蛋白及其制备方法与用途 | |
CN113603794B (zh) | 用于调节血糖和脂质的增效型双功能蛋白 | |
JP2020079301A (ja) | オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物 | |
AU2010246108B2 (en) | FGF21 mutants and uses thereof | |
WO2018032787A1 (zh) | 高糖基化人生长激素融合蛋白及其制备方法与用途 | |
US20120052069A1 (en) | Fgf21 mutants and uses thereof | |
JP7064618B2 (ja) | 増殖分化因子15アゴニスト化合物およびその使用方法 | |
AU2016346864A1 (en) | Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same | |
MX2013014779A (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo. | |
US10023624B2 (en) | Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein | |
WO2019040399A1 (en) | GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS | |
KR102569658B1 (ko) | 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도 | |
US11981718B2 (en) | Dual-function protein for lipid and blood glucose regulation | |
US20240254187A1 (en) | Dual-function protein for lipid and blood glucose regulation | |
CA3085252A1 (en) | Dual-function protein for lipid and blood glucose regulation | |
AU2020204470B1 (en) | Dual-function protein for lipid and blood glucose regulation | |
AU2014202582A1 (en) | FGF21 mutants and uses thereof | |
EP4363439A1 (en) | Chimeric proteins for targeted delivery of growth factors to the glomerulus | |
EA042599B1 (ru) | Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17840761 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 13/06/2019) |
|
ENP | Entry into the national phase |
Ref document number: 3059662 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019021258 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017840761 Country of ref document: EP Effective date: 20190319 |
|
ENP | Entry into the national phase |
Ref document number: 3059662 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: 112019021258 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL, TENDO EM VISTA A NAO ACEITACAO DA ENTRADA NA FASE NACIONAL FACE A INTEMPESTIVIDADE, POIS O PRAZO PARA A REFERIDA ENTRADA EXPIRAVA EM 19/02/2019 (30 MESES CONTADOS DA DATA DE PRIORIDADE) E A ENTRADA SO OCORREU EM 09/10/2019. IMPORTANTE OBSERVAR QUE A DECLARACAO NO AMBITO DA OPINIAO ESCRITA DA FASE INTERNACIONAL NAO TEM O CONDAO DE, POR SI SO, RETIRAR UMA PRIORIDADE DO PEDIDO INTERNACIONAL. ELA APENAS A DESCONSIDERA PARA FINS DA BUSCA REALIZADA PELO ISA. DITO ISSO, A PRIORIDADE CONTINUA VALIDA NO PEDIDO INTERNACIONAL E DEVERIA TER SIDO CONTADO, A PARTIR DELA, O PRAZO PARA A ENTRADA NA FASE NACIONAL DO PEDIDO. FRISE-SE, AINDA, QUE NAO HA NENHUMA EMISSAO DE |